ALKS vs BIIB
ALKS: Alkermes is a neuroscience-focused biopharmaceutical company developing and commercializing therapeutic treatments for complex neurological and psychiatric disorders. BIIB: A pioneer in neuroscience and immunology, Biogen is a major biotechnology company focused on addressing high-unmet medical needs in complex diseases like Alzheimer’s, Multiple Sclerosis, and SMA.
Side-by-side fundamentals
| Metric | ALKS | BIIB | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $52.73 | $202.95 | |
| Market cap as of 2026-08-03 | $8.8B | $30.0B | |
| P/E as of 2026-08-03 | 53.82 | 21.78 | BIIB lower |
| PEG as of 2026-08-03 | -19.70 | 10.99 | ALKS lower |
| Net margin as of 2026-08-03 | +9.8% | +13.8% | BIIB higher |
| Gross margin as of 2026-08-03 | +86.6% | +75.5% | ALKS higher |
| Operating margin as of 2026-08-03 | +12.3% | +17.5% | BIIB higher |
| ROE as of 2026-08-03 | +8.8% | +7.5% | ALKS higher |
| ROA as of 2026-08-03 | +5.4% | +4.7% | ALKS higher |
| Debt / equity as of 2026-08-03 | 0.86 | 0.34 | BIIB lower |
| Revenue growth (YoY) as of 2026-08-03 | +3.2% | +1.2% | ALKS higher |
| Revenue CAGR (3y) SEC XBRL | +9.9% | -0.9% | ALKS higher |
| Beta as of 2026-08-03 | 0.26 | 0.48 | |
| 1-year return as of 2026-07-27 close | +101.8% | +58.6% | ALKS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.